Molecularly targeted therapies in advanced renal-cell carcinoma — optimisation of first-line therapy
Abstract
Currently, systemic treatment of advanced renal-cell carcinoma is based on targeted therapy, mostly including
tyrosine kinases inhibitors with anti-VEGF activity. The achieved effect is cytostatic. The systemic treatment is
conducted in a sequential manner. The choice of the first-line treatment agent is crucial but may be problematic
due to the lack of molecular predictors. Sunitinib and pazopanib are the tyrosine kinases inhibitors of choice in
the first-line therapy. They differ in terms of their selectivity in cellular kinome inhibition. In effect, they also have
a different toxicity profile and influence on the patient’s quality of life during the therapy. These differences are
important when choosing the optimal treatment. The superiority of the both drugs over one another has been
discussed for years. The article is a review of this issue.
Keywords: renal-cell carcinomamolecularly targeted therapytyrosine kinase inhibitorssunitinibpazopanib
References
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115–124.
- Motzer R, Hutson T, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009; 27(22): 3584–3590.
- Sternber CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6): 1061–1068.
- Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. E J Cancer. 2013; 49(6): 1287–1296.
- Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014; 32(14): 1412–1418.
- Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8): 722–731.
- Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Journal Cancer. 2015; 65: 102–108.
- Heng DYC, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014; 25(1): 149–154.